Affiliation:
1. School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi'an, 710061, China
2. NMPA Key
Laboratory for Quality Control of Traditional Chinese and Tibetan Medicine, Qinghai Provincial Drug Inspection
and Testing Institute, Xining, 810016, China
Abstract
Abstract:
Leukemia is a malignant clonal disease of hematopoietic stem cells, which accounts
for about 3% of the total incidence of tumors and is particularly prevalent among
children and adolescents. It mainly includes four types of leukemia, namely ALL, AML,
CLL, and CML, which are often aggressive and challenging diseases to treat. Several signaling
pathways are dysregulated in almost all types of leukemia, such as JAK, PI3K, and
MAPK, and others are dysregulated in specific types of leukemia, like Wnt/β-catenin,
Hedgehog, FLT3, Bcr-Abl, and so on. Many efforts have been devoted to developing
small molecule inhibitors targeting protein kinases involved in leukemia-related signaling
pathways. In this review, we focus on the study of signaling pathways and protein kinases
that developed as targets of anti-leukemia drug therapy and report the research progress of
relevant small molecule kinase inhibitors over the last five years.
Publisher
Bentham Science Publishers Ltd.